Seeking Alpha

Eli Lilly (LLY -0.5%) is halting the development of its mGlu2/3 schizophrenia drug after a...

Eli Lilly (LLY -0.5%) is halting the development of its mGlu2/3 schizophrenia drug after a recent analysis indicated that the treatment was unlikely to succeed in a second Phase III trial, having already failed in a previous study. Another mid-stage trial, which was testing Glu2/3 as an adjunctive treatment with atypical antipsychotics, was unable to meet the main study goal. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|